Last reviewed · How we verify

Budesonide 200 µg plus formoterol 6 µg DPI — Competitive Intelligence Brief

Budesonide 200 µg plus formoterol 6 µg DPI (Budesonide 200 µg plus formoterol 6 µg DPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Budesonide 200 µg plus formoterol 6 µg DPI (Budesonide 200 µg plus formoterol 6 µg DPI) — Chiesi Farmaceutici S.p.A.. Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Budesonide 200 µg plus formoterol 6 µg DPI TARGET Budesonide 200 µg plus formoterol 6 µg DPI Chiesi Farmaceutici S.p.A. phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/formoterol Turbuhaler Budesonide/formoterol Turbuhaler AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide / Formoterol Budesonide / Formoterol Brigham and Women's Hospital marketed Inhaled corticosteroid / long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+ Symbicort Turbohaler without Turbo+ Istituto per la Ricerca e l'Innovazione Biomedica marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
CHF1535 CHF1535 Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg budesonide/formoterol Turbuhaler 320/9µg AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
FF FF GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

  1. GlaxoSmithKline · 14 drugs in this class
  2. Pearl Therapeutics, Inc. · 5 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. Research in Real-Life Ltd · 3 drugs in this class
  5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
  6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
  7. Johns Hopkins University · 1 drug in this class
  8. National Jewish Health · 1 drug in this class
  9. SkyePharma AG · 1 drug in this class
  10. University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budesonide 200 µg plus formoterol 6 µg DPI — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-200-g-plus-formoterol-6-g-dpi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: